16 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
a team of employees and consultants to oversee our technical quality and CMOs. Our lead product, XDEMVY, and our product candidate, TP-03
ARS
2022 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 23
Annual report to shareholders
4:08pm
candidates. We have assembled a team of employees and consultants to oversee our technical quality and CMOs. The product candidate TP-03 includes
8-K
4moc6ajhabq85vjm
12 Oct 22
Departure of Directors or Certain Officers
4:21pm
8-K
9az9mvnihcw9puwl2cd
12 Aug 21
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors
4:01pm
DEF 14A
j48m64vg 5sfwzpjsu
30 Apr 21
Definitive proxy
4:03pm
10-K
u5x2 t1c1x81kd6
31 Mar 21
Annual report
5:01pm
424B4
8905u
16 Oct 20
Prospectus supplement with pricing info
4:40pm
S-1/A
o97qd 7w4c2d3r
9 Oct 20
IPO registration (amended)
5:16pm
S-1
q15q7vefeg m490w
25 Sep 20
IPO registration
5:25pm
DRS/A
v34aptk
14 Sep 20
Draft registration statement (amended)
12:00am
DRS
1tkyi31j7x7 n0adwvk6
7 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next